Shares of Hologic, Inc. (NASDAQ:HOLX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the fifteen analysts that are covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $89.50.
HOLX has been the topic of several research reports. Wolfe Research initiated coverage on shares of Hologic in a research report on Friday, December 13th. They set a "peer perform" rating on the stock. Citigroup cut Hologic from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $95.00 to $85.00 in a report on Tuesday, October 1st. Raymond James raised their price objective on Hologic from $93.00 to $95.00 and gave the company an "outperform" rating in a report on Tuesday, November 5th. Mizuho cut their target price on Hologic from $90.00 to $87.00 and set an "outperform" rating for the company in a research note on Tuesday, November 5th. Finally, Jefferies Financial Group initiated coverage on shares of Hologic in a research note on Tuesday, December 10th. They set a "hold" rating and a $85.00 price target on the stock.
Read Our Latest Report on Hologic
Insider Buying and Selling at Hologic
In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the firm's stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 1.75% of the company's stock.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. Principal Financial Group Inc. increased its stake in shares of Hologic by 3.6% in the 3rd quarter. Principal Financial Group Inc. now owns 269,546 shares of the medical equipment provider's stock worth $21,957,000 after acquiring an additional 9,419 shares in the last quarter. Oddo BHF Asset Management Sas bought a new position in shares of Hologic during the third quarter valued at approximately $1,110,000. Franklin Resources Inc. lifted its holdings in shares of Hologic by 171.7% during the third quarter. Franklin Resources Inc. now owns 278,295 shares of the medical equipment provider's stock valued at $22,714,000 after purchasing an additional 175,855 shares during the last quarter. Tidal Investments LLC boosted its position in shares of Hologic by 60.1% in the 3rd quarter. Tidal Investments LLC now owns 15,351 shares of the medical equipment provider's stock worth $1,250,000 after purchasing an additional 5,764 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new stake in shares of Hologic in the 3rd quarter worth approximately $93,000. Institutional investors own 94.73% of the company's stock.
Hologic Price Performance
Shares of HOLX stock traded up $0.89 on Friday, reaching $71.65. The company's stock had a trading volume of 8,560,791 shares, compared to its average volume of 1,672,050. The company has a market capitalization of $16.26 billion, a P/E ratio of 21.52, a PEG ratio of 2.38 and a beta of 0.96. Hologic has a 12-month low of $70.36 and a 12-month high of $84.67. The stock's 50 day simple moving average is $78.49 and its 200-day simple moving average is $78.53. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49.
Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. The firm had revenue of $987.90 million for the quarter, compared to analysts' expectations of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company's revenue was up 4.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.89 EPS. As a group, equities analysts predict that Hologic will post 4.28 earnings per share for the current fiscal year.
Hologic Company Profile
(
Get Free ReportHologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Recommended Stories
Before you consider Hologic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.
While Hologic currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.